Transforming somatic mutations of mammalian target of rapamycin kinase in human cancer

Hiroyuki Yamaguchi,1,2 Masahito Kawazu,3 Takahiko Yasuda,1 Manabu Soda,1 Toshihide Ueno,1 Shinya Kojima,1 Masakazu Yashiro,4 Ichiro Yoshino,3 Yuichi Ishikawa,4 Eirin Sai,1 and Hiroyuki Mano1

1Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, Tokyo; 2Department of Internal Medicine, Nagasaki University Hospital, Nagasaki; 3Department of Medical Genomics, Graduate School of Medicine, The University of Tokyo, Tokyo; 4Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka; 5Department of General Thoracic Surgery, Graduate School of Medicine, Chiba University, Chiba; 6Department of Pathology, The Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan

Key words
Cancer genomics, molecularly targeted therapy, mammalian target of rapamycin, oncogene, somatic mutation

Correspondence
Hiroyuki Mano, Department of Cellular Signaling, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-0033, Japan; Tel.: +81-3-5841-0633; Fax: +81-3-5841-0634; E-mail: hmano@m.u-tokyo.ac.jp

Funding Information
Japan Agency for Medical Research and Development; Ministry of Health, Labor, and Welfare of Japan; Japan Society for the Promotion of Science.

Received March 16, 2015; Revised September 24, 2015; Accepted September 26, 2015

Cancer Sci 106 (2015) 1687–1692
doi: 10.1111/cas.12828

Mammalian target of rapamycin (mTOR) is a serine–threonine kinase and a component, together with the rapamycin-sensitive regulatory associated protein of mTOR or the rapamycin-insensitive companion of mTOR, of mTOR complex 1 (mTORC1) or mTORC2, respectively.1–3 From its amino-terminus, mTOR contains HEAT (huntingtin, elongation factor 3, protein phosphatase 2A, TORI) repeat, FAT (FRAP, ATM, TRRAP), FRB (FK506-rapamycin binding), amino-terminal lobe of the kinase, LBE (LST8 binding element), carboxyl-terminal lobe of the kinase, and FATC (FRAP, ATM, TOR at C-terminus) domains. Whereas the molecular mechanism by which the kinase activity of mTOR is regulated remains unclear, mTOR acts downstream of the phosphatidylinositol 3-kinase (PI3K) signaling pathway. One cascade leading to mTOR activation, for instance, involves activation of the serine–threonine kinase AKT in a manner dependent on PI3K, phosphorylation of tuberous sclerosis complex (TSC) 1/2 by AKT, consequent loading of Rheb with GTP, and activation of mTORC1. Ligand binding to many receptor-type tyrosine kinases thus results in the activation of mTOR through PI3K.

Activated mTOR regulates a plethora of cellular activities including gene transcription, translation, cell growth and proliferation, apoptosis, and autophagy.1–3 For example, mTOR phosphorylates and thereby activates p70 S6 kinase (p70S6K), which is a positive regulator of cell size and mRNA translation.4–6 Also, eukaryotic translation initiation factor 4E binding protein 1 (eIF4E-BP1) becomes directly phosphorylated by mTOR, and dissociated from eukaryotic translation initiation factors, allowing ribosome entry into 4E-cap site of mRNAs.

Consistent with the importance of mTOR in the regulation of cell growth and proliferation as well as of protein synthesis, multiple genetic alterations that lead to mTOR activation have been identified in human cancers.5,6 Activating somatic mutations in the catalytic subunit of PI3K, for instance, are among the most frequent oncogenic changes in tumors. Loss-of-function mutations of phosphatase and tensin homolog, which counteracts PI3K activity, are also frequently detected. Activating mutations of AKT1 and AKT3 have been associated with breast cancer and melanoma, respectively, and genetic loss of TSC1 has been observed. Such genetic changes commonly lead to the activation of mTOR, and blockade of such signaling with mTOR-specific inhibitors has proven to be of clinical benefit.
Whether mTOR itself becomes a bona fide oncoprotein as a result of somatic genomic alterations in cancer has remained elusive. Forced introduction of amino acid substitutions into mTOR has been shown to result in activation of its kinase function, or to confer transforming activity,\(^{(7-9)}\) whereas deletion of the inhibitory domain also leads to mTOR activation,\(^{(10)}\) revealing an oncogenic potential for mTOR. Sato et al.\(^{(11)}\) searched non-synonymous mTOR mutations in the COSMIC cancer mutation database (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/), and found seven independent mutations. Then they revealed that E2419K, S2215Y, and R2505P substitutions eluate enzymatic activity of mTOR, but failed to demonstrate transforming ability. Thus, it is not settled yet if mTOR mutations found in human cancer confer direct transforming potential.

We have now identified somatic single nucleotide variations in a specimen of a large cell neuroendocrine carcinoma (LCNEC), one of which results in a Leu\(^{2209}\)-to-Val substitution in mTOR. The mTOR(L2209V) mutant was found not only to mediate marked phosphorylation of p70S6K but also to possess transforming ability when expressed in mouse 3T3 fibroblasts. Moreover, approximately half of the amino acid substitutions in mTOR listed in the cancer database similarly confer oncogenic activity.

Materials and Methods

Clinical specimens and cell lines. Surgically resected tumor and paired normal specimens from LCNEC patients were analyzed with written informed consent. This study was approved by the institutional ethics committees of The University of Tokyo (Tokyo, Japan) and Chiba University (Chiba, Japan). Mouse 3T3 and HEK293T cells were obtained from ATCC (Manassas, VA, USA), and were maintained in DMEM-F12 supplemented with 10% FBS and 2 mM L-glutamine (all from Thermo Fisher Scientific, Waltham, MA, USA), and were maintained in DMEM-F12 supplemented with 5% calf serum (Invitrogen) for up to 2 weeks. Cell transformation was assessed either by phase-contrast microscopy or by staining with the Giemsa solution.

For immunoblot analyses, 3T3 cells were lysed by NP-40 lysis buffer containing 1% NP-40, 50 mM Tris-HCl, 150 mM NaCl, 0.1% SDS, 1% protease inhibitors. Nuclear extracts were prepared by cell lysis with 1% NP-40, 50 mM Tris-HCl, 150 mM NaCl, and protein phosphatase 2A, TORI; LBE, LST8 binding domain. HEAT, huntingtin, elongation factor 3, bar = 100 µm. FAT, FRAP, ATM, TRRAP; FATC, FRAPP, ATM, TOR at C-terminus; FRB, FK506-rapamycin binding; HEAT, huntingtin, elongation factor 3, protein phosphatase 2A, TORI; LBE, LST8 binding element.

Fig. 1. Transforming activity of the mammalian target of rapamycin (mTOR(L2209V)) mutant. (a) Domain organization of human mTOR showing the positions of non-synonymous mutations (transforming ones shown in red) detected in human cancers. (b) Sequencing electrophoretograms for PCR products corresponding to the region of the mTOR gene containing codon 2209 that were obtained from large cell neuroendocrine carcinoma tumor #G4T or its paired normal sample. (c) Mouse 3T3 fibroblasts infected with recombinant retroviruses encoding v-Ras, mTOR, or mTOR(L2209V), or with the corresponding empty virus (Mock), were cultured in the presence of 5% calf serum for 12 days and then examined by phase-contrast microscopy. Scale bar = 100 µm. FAT, FRAP, ATM, TRRAP; FATC, FRAPP, ATM, TOR at C-terminus; FRB, FK506-rapamycin binding; HEAT, huntingtin, elongation factor 3, protein phosphatase 2A, TORI; LBE, LST8 binding element.
NaCl, 1 mM sodium fluoride, 1 mM sodium vanadate, and 1 mM PMSF (all from Sigma-Aldrich). Cell lysates were separated by 7.5% SDS-PAGE, and subjected to immunoblot analysis. Antibodies used were #2972 for mTOR, #9202 for p70S6K, #9234 for phosphorylated p70S6K, #2217 for S6RP, #4857 for phosphorylated S6RP, #9644 for 4EBP1, #2855 for phosphorylated 4EBP1, #4691 for AKT, #4060 for phosphorylated AKT, and #4970 for ACTB (all from Cell Signaling Technology, Danvers, MA, USA). Rapamycin was obtained from Merck Millipore (Billerica, MA, USA).

For the cell number analysis, 1 × 10^4 of 3T3 cells at 48 h after the infection with recombinant retrovirus were seeded into each well of 96-well plates. The next day, the medium was changed to DMEM-F12 with various concentrations of calf serum, and further cultured for 36 h. Cell number was assessed with a luminometer by using CellTiter-Glo Luminescent Cell Viability assay (Promega, Madison, WI, USA). At the same time, cells were subjected to measuring the caspase 3/caspase 7 activity by using the Caspase-Glo 3/7 assay system (Promega).

Results

mTOR(L2209V) is a transforming mutant. Full-exome sequencing for an LCNEC specimen (#G4T) and its paired normal cells (PBMCs) obtained from a 70-year-old man identified a total of 167 somatic missense single nucleotide variations (Table S1) including one for a Leu2209-to-Val substitution in mTOR (Fig. 1a, Table S2). Sanger sequencing of the #G4T genome confirmed a heterozygous C-to-G mutation in codon 2209 (Fig. 1b). Given that it has been unclear whether mTOR can function as an oncoprotein as a result of its own genomic changes in cancer, we examined the transforming ability of mTOR(L2209V) in a focus formation assay. Expression of mTOR(L2209V) induced marked transformation of mouse 3T3 cells, whereas that of the wild-type protein did not (Fig. 1c). As a positive control, the v-Ras oncoprotein also readily transformed 3T3 cells, although the morphology of the transformed cells was distinct from that of those expressing mTOR (L2209V). These results indicated that mTOR can become a bona fide oncoprotein as a result of a somatic mutation found in human cancer.

Various amino acid substitutions confer transforming ability on mTOR. Our exome sequencing of other LCNEC samples did not reveal additional tumors positive for mTOR(L2209V), but iden-

Fig. 2. Transforming amino acid changes in mammalian target of rapamycin (mTOR). Mouse 3T3 cells were infected with recombinant retroviruses encoding each mTOR mutant, wild-type mTOR, or v-Ras or with the corresponding empty virus (Mock). The cells were cultured in the presence of 5% calf serum for 10 days and then stained with Giemsa solution.

Fig. 3. Intracellular signaling evoked by transforming mammalian target of rapamycin (mTOR) mutants and rapamycin sensitivity of transforming activity. (a) Mouse 3T3 cells were lysed 3 days after infection with recombinant retroviruses encoding wild-type or transforming mutants of mTOR. The cell lysates were subjected to immunoblot analysis with antibodies to total or phosphorylated (p-) forms of the indicated proteins. ACTB served as a loading control. (b) Mouse 3T3 cells infected with recombinant retroviruses encoding v-Ras, wild-type mTOR, mTOR(T1977I), mTOR(L2209V), or mTOR(S2215Y) were cultured in the presence of 5% calf serum (CS) and with or without 100 pM rapamycin for 12 days and then examined by phase-contrast microscopy. Scale bar = 1 mm.

identified two independent somatic non-synonymous mutations (p.D258H and p.R1235P) of mTOR (data not shown). Searches of the COSMIC database as well as our in-house sequencing data for mTOR mutations identified an additional 26 amino acid
substitutions in various cancer specimens and the OCUM-2M gastric cancer cell line (Fig. 1a, Table S2). Of note, recurrent sites for missense mutations, including Thr1977 and Ser2215, were apparent.

We constructed recombinant retroviruses encoding each of the identified mTOR mutants and used them for focus formation assays with mouse 3T3 cells. Unexpectedly, approximately half of these mutants manifested transforming activity (Fig. 2, Fig. S1). Whereas the morphology of the transformed cells appeared similar (Fig. S1), the extent of the malignant change (the number of piled-up foci) varied substantially among the mutants. For example, mTOR(T1977K), mTOR(T1977R), mTOR(S2215F), and mTOR(S2215Y) showed marked transforming potential, whereas that of mTOR(L2220F) and mTOR(D2512H) appeared less pronounced.

Intracellular signaling evoked by oncogenic mTOR. The various transformed 3T3 cell lines were then examined for the activation status of signaling molecules downstream to mTOR (Fig. 3a). First, immunoblot analysis with antibodies to mTOR revealed that each mTOR mutant was expressed at a similar level, although some mutants (such as R2505P) were more abundant than the others. Phosphorylation of p70S6K at Thr389 was induced by most of the transforming mutants, although such induction was minimal or non-existent for mTOR(E1799K), mTOR(L2220F), and mTOR(D2512H). Of note, the ability of the mutants to phosphorylate p70S6K appeared to correlate approximately with their transforming potential (Fig. 2, Fig. S1). Activated p70S6K phosphorlates S6 ribosomal protein (S6RP), which in turn promotes mRNA translation. Marked phosphorylation of S6RP at Ser235/236 was evident in the 3T3 cell lines that manifested increased activation of p70S6K (Fig. 3a). Similarly, 4EBP1, another substrate of mTOR, was phosphorylated at Thr37/46 in 3T3 cells expressing the transforming.
mTOR mutants, although to a lesser extent compared with S6RP phosphorylation.

Whereas mTORC2 directly phosphorylates AKT, activated p70S6K phosphorylates and negatively regulates insulin receptor substrate 1 (IRS-1). As insulin receptor substrate 1 is an important upstream activator of PI3K–AKT, phosphorylation of p70S6K, thus, evokes a physiological negative feedback loop toward AKT. Phosphorylation of AKT at Ser 473 was slightly attenuated in 3T3 cells expressing active mTOR mutants compared with that in those expressing the wild-type protein (Fig. 3a), consistent with a previous observation.18

Transforming activity of mTOR mutants is rapamycin sensitive. Mammalian target of rapamycin acts as a catalytic subunit of both mTORC1 and mTORC2. Given that the macrolide rapamycin inhibits the activity of mTORC1, but not that of mTORC2 in vitro,14 we tested whether the transforming activity of mTOR mutants is sensitive to rapamycin. Mouse 3T3 cells expressing T1977I, L2209, or S2215Y mutants of mTOR (which are among those with the greatest transforming activity) were subjected to a focus formation assay in the absence or presence of 100 nM rapamycin. Whereas all three mutants (but not the wild-type protein) generated malignant foci in the absence of rapamycin, this effect was not apparent in the presence of the drug (Fig. 3b, Fig. S2). The transforming ability of these mTOR mutants is thus sensitive to rapamycin.

Cell survival signaling by oncogenic mTOR mutants. Active mTORC1 and mTORC2 induce cell survival signals.15 We therefore examined whether transforming mutation of mTOR promotes cell survival. The 3T3 cells infected with recombinant retroviruses encoding wild-type mTOR, mTOR(T1977I), mTOR(L2209V), or mTOR(S2215Y) were cultured in the presence of 5%, 0.5%, or 0% calf serum for 36 h (Fig. 4a, b). Whereas cells infected with the empty virus proliferated in the presence of 5% serum, they ceased to do so in the presence of 0.3% or 0% serum. Similarly, 3T3 cells infected with the virus for wild-type mTOR decreased in number as the serum concentration decreased. In contrast, cells expressing the transforming mutants of mTOR continued to proliferate even in the absence of serum. Cells expressing v-Ras also generated abnormal foci under all three serum conditions. The serum deprivation-induced activation of caspase 3/caspase 7 was partially suppressed when 3T3 cells expressed v-Ras or active mTOR mutants (Fig. 4c). Therefore, oncogenic mutations of mTOR confer anti-apoptotic functions as well.

Discussion

We have here shown that mTOR becomes activated and acquires direct transforming ability as a result of amino acid substitutions found in human cancer cells. The mTOR gene thus becomes an oncogene through genetic alteration. However, we failed to observe tumor formation in a nude mouse tumorigenicity assay for 3T3 cells expressing mTOR mutants, whereas those expressing v-Ras did generate s.c. tumors in the same observation period (data not shown). The transforming ability of mTOR mutants may, therefore, be less potent than that of v-Ras.

As expected, oncogenic mTOR mutants activated downstream signaling molecules such as p70S6K, S6RP, and 4EBP1 in 3T3 cells. Furthermore, cells expressing such mTOR mutants were more resistant to nutrient deprivation than were those expressing the wild-type protein. Our observations that the proliferation of cells expressing these mTOR mutants was sensitive to rapamycin and that AKT was not activated in these cells suggest that such mutants exert their transforming action through mTORC1. Artificially generated active mutants of mTOR similarly confer resistance to nutrient deprivation and induce phosphorylation of S6RP.17 However, given that long-time treatment with rapamycin can also affect mTORC2 activity in some cell types,16 whether mTORC1 is the only complex that mediates the starvation resistance of cells expressing transforming mTOR mutants requires further examination.

Yang et al17 reported that artificially generated transforming mutations are widely distributed in the 3-D structure of mTOR. They are enriched in several “limiting active-site access” regions including the catalytic cleft and the amino-terminal portion of FAT. In contrast, most of the naturally occurring transforming mutations (E1799K, L2209V, S2215F/Y, L2220I, V2406A, R2505S, and D2512H) cluster in an unexpectedly narrow region of the structure (Fig. 5). They are thus localized at an interacting surface between the carboxyl-terminal lobe of the kinase domain and the FAT domain, the latter of which forms a “C”-shaped clamp for the former. Whether these mutations loosen the binding between the FAT and kinase domains and thereby render the kinase domain more open and active remains to be determined. Our findings suggest that the FAT domain plays a key role in the regulation of mTOR activity.

The FRB domain is thought to function as a gatekeeper for the mTOR catalytic site.17 It prevents the entry of non-substrate peptides, but allows that of genuine ones. Importantly, two activating mutation sites (Thr1977 and Val2006) are positioned close to each other in the vicinity of the FRB domain. In general, transforming mutations of protein tyrosine kinases cluster in the activation loop of the catalytic domain. In contrast, groups of activating mutation sites, such as those in the vicinity of the FRB and FAT domains, are located outside of the catalytic domain in mTOR. This finding may be due to the fact that mTOR is intrinsically active and negatively regulated by the FRB and FAT domains.17

We have thus shown that mTOR becomes an oncokinase in human cancer as a result of amino acid substitutions, and that
the transforming activity of this oncokine is sensitive to rapamycin. Inhibitors of mTOR are currently in use clinically for the treatment of renal cell carcinoma, but whether such tumors harbor oncogenic mTOR mutations is not examined in the clinics. Our results have shown that transforming mTOR mutants are distributed across various cancer types (albeit at a low frequency), suggesting that clinical trials with mTOR inhibitors are warranted for individuals with such tumors positive for oncogenic mTOR mutations.

Acknowledgments

This study was supported in part by a grant for Leading Advanced Projects for medical innovation from the Japan Agency for Medical Research and Development, by a grant for Research on Development of New Drugs from the Ministry of Health, Labor, and Welfare of Japan, and by Grants-in-Aid for Scientific Research (C) and for Young Scientists (B) from the Japan Society for the Promotion of Science.

Disclosure Statement

The authors have no conflict of interest.

Supporting Information

Additional supporting information may be found in the online version of this article:

Fig. S1. Focus formation assay for mammalian target of rapamycin (mTOR) mutants. Mouse 3T3 cells were infected with recombinant retroviruses encoding each mTOR mutant shown in Figure 1(a), wild-type mTOR, or v-Ras or with the corresponding empty virus (Mock). The cells were cultured for 10 days in the presence of 5% calf serum and then examined by phase-contrast microscopy. Scale bar = 100 μm.

Fig. S2. Transforming activity of mammalian target of rapamycin (mTOR) mutants is rapamycin sensitive. Mouse 3T3 cells infected with recombinant retroviruses encoding v-Ras, wild-type mTOR, mTOR(T1977I), mTOR(L2209V), or mTOR(S2215Y) were cultured in the presence of 5% calf serum and with or without 100 pM rapamycin for 12 days and then stained with Giemsa solution.

Fig. S3. Positions of Thr1977 and Val2006 in human mammalian target of rapamycin (mTOR). The 3-D structure of mTOR is shown schematically as in Figure 5. Thr1977, Val2006, and ATP are shown as spherical models.

Table S1. Somatic missense single nucleotide variations detected in patient #G4T with large cell neuroendocrine carcinoma.

Table S2. Non-synonymous mutations of mammalian target of rapamycin (mTOR) in human cancer.

References

1 Sarbassov DD, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. 
Cancer Sci | December 2015 | vol. 106 | no. 12 | 1692

2 Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer 2005; 5: 921–9.

3 Xu K, Liu P, Wei W. mTOR signaling in tumorigenesis. Biochim Biophys Acta 2014; 1846: 638–54.

4 Hay N, Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004; 18: 1926–45.

5 Sabatini DM. mTOR and cancer: insights into a complex relationship. Nat Rev Cancer 2006; 6: 729–34.

6 Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550–62.

7 Urano T, Sato T, Matsuo T, Otsubo Y, Yamamoto M, Tamanoi F. Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells. Proc Natl Acad Sci USA 2007; 104: 3514–9.

8 Ohne Y, Takahara T, Hatakeyama R et al. Isolation of hyperactive mutants of mammalian target of rapamycin. J Biol Chem 2008; 283: 31861–70.

9 Murugan AK, Alzahrani A, Xing M. Mutations in critical domains confer the human mTOR gene strong tumorigenicity. J Biol Chem 2013; 288: 6511–21.

10 Sekulic A, Hudson CC, Homme JL et al. A direct linkage between the phos- phoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000; 60: 3504–13.

11 Sato T, Nakashima A, Guo L, Coffman K, Tamanoi F. Single amino-acid changes that confer constitutive activation of mTOR are discovered in human cancer. Oncogene 2010; 29: 2746–52.

12 Yashiro M, Chung YS, Nishimura S, Inoue T, Sowa M. Establishment of two new sarcomatous gastric cancer cell lines: analysis of factors associated with disseminated metastasis. Br J Cancer 1995; 72: 1200–10.

13 Zick Y. Ser/Thr phosphorylation of IRS proteins: a molecular basis for insulin resistance. Sci Signal 2005; 2005: pe4.

14 Jacinto E, Loewith R, Schmidt A et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004; 6: 1122–8.

15 Hung CM, Garcia-Haro L, Sparks CA, Guerlin DA. mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol 2012; 4: a008771.

16 Sarbassov DD, Ali SM, Sengupta S et al. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 2006; 22: 159–68.

17 Yang H, Rudge DG, Koos JD, Vaidalangam B, Yang HJ, Pavletich NP. mTOR kinase structure, mechanism and regulation. Nature 2013; 497: 217–23.

© 2015 The Authors. Cancer Science published by Wiley Publishing Asia Pty Ltd on behalf of Japanese Cancer Association.